Trial Profile
Phase I trial of S-1 plus Lapatinib in patients with HER-2 positive metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2018
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Lapatinib (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 09 Feb 2018 Status changed from recruiting to completed.
- 25 Jan 2011 New trial record